Obinutuzumab a Success in Phase 3 Trial for Lupus Nephritis
Adding the anti-CD2src monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone,...
Lawanda Grumbles
Adding the anti-CD2src monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone,...
